







## Landmark Trials

UPLIFT*		Chronic obstructive pulmonary disease (COPD)	8,018 patients
RE-LY*		Stroke	18,113 patients
ONTARGET™		Cardiovascular protection	25,620 patients
TRANSCEND*		Cardiovascular protection	5,926 patients
ECASS 3™		Stroke	821 patients
PRoFESS*		Stroke	20,332 patients